ISPOR 2022 – Paying for Digital Therapeutics (DTx): What Evidence Is Needed?
March 7, 2022
There is currently no consensus between stakeholders on the value of DTx, or software-based approaches to treatment or prevention of health conditions. In an interactive discussion at ISPOR 2022, panelists will present their viewpoints and data and debate various ways that payers, providers, digital innovators, and patients can reach an agreement on how to perform accurate value assessments of digital health solutions. The panel takes place on Tuesday, May 17th, 2022.
According to ISPOR, “OVERVIEW: Biopharma companies have embraced DTx and studies have shown to improve outcomes from DTx, either alone or in conjunction with conventional protocols. While there is some optimism in DTx circles that COVID-19 will accelerate acceptance and use of these promising treatment options, the DTx sector as a whole is still in the early stages of development and the needs for payers to evaluate these products is not well understood.”
Click here to learn more.
(Source: ISPOR, March 7th, 2022)